Show simple item record

dc.creatorKang,Youra
dc.creatorTimilshina,Maheshwor
dc.creatorNam,Tae-gyu
dc.creatorJeong,Byeong-Seon
dc.creatorChang,Jae-Hoon
dc.date2017-01-01
dc.date.accessioned2019-05-02T21:22:36Z
dc.date.available2019-05-02T21:22:36Z
dc.identifierhttps://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0716-97602017000100202
dc.identifier.urihttp://revistaschilenas.uchile.cl/handle/2250/82680
dc.descriptionAbstract Background CD4+ T cells play an important role in the initiation of an immune response by providing help to other cells. Among the helper T subsets, interferon-γ (IFN-γ)-secreting T helper 1 (Th1) and IL-17-secreting T helper 17 (Th17) cells are indispensable for clearance of intracellular as well as extracellular pathogens. However, Th1 and Th17 cells are also associated with pathogenesis and contribute to the progression of multiple inflammatory conditions and autoimmune diseases. Results In the current study, we found that BJ-1108, a 6-aminopyridin-3-ol analogue, significantly inhibited Th1 and Th17 differentiation in vitro in a concentration-dependent manner, with no effect on proliferation or apoptosis of activated T cells. Moreover, BJ-1108 inhibited differentiation of Th1 and Th17 cells in ovalbumin (OVA)-specific OT II mice. A complete Freund’s adjuvant (CFA)/OVA-induced inflammatory model revealed that BJ-1108 can reduce generation of proinflammatory Th1 and Th17 cells. Furthermore, in vivo studies showed that BJ-1108 delayed onset of disease and suppressed experimental autoimmune encephalomyelitis (EAE) disease progression by inhibiting differentiation of Th1 and Th17 cells. Conclusions BJ-1108 treatment ameliorates inflammation and EAE by inhibiting Th1 and Th17 cells differentiation. Our findings suggest that BJ-1108 is a promising novel therapeutic agent for the treatment of inflammation and autoimmune disease.
dc.formattext/html
dc.languageen
dc.publisherSociedad de Biología de Chile
dc.relation10.1186/s40659-017-0113-z
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourceBiological Research v.50 2017
dc.subjectBJ-1108
dc.subjectTh1/Th17 cell
dc.subjectDifferentiation
dc.subjectEAE
dc.titleBJ-1108, a 6-Amino-2,4,5-trimethylpyridin-3-ol analogue, regulates differentiation of Th1 and Th17 cells to ameliorate experimental autoimmune encephalomyelitis


This item appears in the following Collection(s)

Show simple item record